Seres Therapeutics, Inc. MCRB
It was a pretty slow start to the week yesterday with the markets gapping up early, but falling into decline throughout the session. That didn’t stop the one fresh idea we did have in our morning report from posting a respectable performance on the day.
We referred to MCRB as a ‘prime bottom play’ and while it didn’t exactly explode out of the gate, what we did see was certainly a step in the right direction. From a low of 2.63, the stock ran a modest but solid 16% to a high of 3.06. More importantly, it preserved its momentum by holding the three-dollar mark into the close. A good first day by any stretch of the imagination.
We’ll continue to monitor our longer term options idea that we included, the MCRB 07/19 $2.50 Calls which stand to do well in coming weeks if the stock can continue to maintain the current trend. Yesterday’s session was the fourth consecutive day that the stock has recorded higher lows, and we’ll want to see more of that moving forward.
Verastem Inc. VSTM
Speaking of bottom plays, we’ve got another one to add to our radars this morning in VSTM. This stock has lost a ton of value over the past year, and recently began to show signs of a rebound. We like it for its technical setup and volatility potential. We will remain interested in tracking VSTM for as long as it can maintain support at 1.72 or better.
VSTM is considered by some to be a speculative buyout play as well. Just this week the company has reported positive early stage data on Copiktra, the company’s leukemia treatment under development. Definitely an interesting story to follow.
Celestica Inc. CLS
Perhaps even more attractive as a bottom play than the above mentioned stock, we’ve got CLS, which just began to show signs of life after recording a new annual low at the beginning of this month.
If the stock can manage to break its 50DMA at 7.09, there’s a real chance that it could produce significant gains, filling the gap to the topside on the chart. Interesting to naote about CLS as well, is that the company’s EPS has grown by nearly 90% over the past year. When taking that into consideration, its current valuation doesn’t make a whole lot of sense.
CBAY, DERM, SAVA, NERV, NDRA, PHUN, VIVE